Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 7916-7922
DOI: 10.1111/dom.70923 ↗At a glance
Beobachtungsstudie in Diabetes, Obesity and Metabolism, published online on 2026-06-14. Written by Casey P Durand and 5 co-authors. Institution: Evernorth Health Services, Evernorth Research Institute, St. Louis, Missouri, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Cited 1 times so far (Crossref); 23 references. The full text is freely available in PubMed Central.
Topics: Diabetes mellitus
Abstract (original language)
Aims
To analyse the healthcare cost trajectories following the initiation of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) or dipeptidyl peptidase‐4 inhibitor (DPP‐4i) therapy in patients with type 2 diabetes. Materials and Methods We conducted a difference‐in‐difference study using member‐level claims data from a national pharmacy benefit manager. Treatment‐naïve patients were categorised into three groups based on the drug they initiated first. The first fill date in 2020 or 2021 was the index date, with a one‐year look‐back period and 2 years of follow‐up. Propensity score weighting balanced the groups. We used generalised estimating equations to analyse year‐over‐year changes in per patient per month (PPPM) costs for medical, pharmacy and total cost of care expenditures.
Results
Changes in medical costs were not statistically different across drug groups in years 1 and 2. In contrast, the increase in pharmacy costs in the first year for GLP‐1 RA was significantly higher than the other two drugs. Driven primarily by pharmacy costs, total cost of care trajectories showed similar between‐drug differences.
Conclusion
Patients with type 2 diabetes initiating on a GLP‐1 RA show significantly higher pharmacy cost patterns as compared to the DPP‐4i and SGLT‐2i groups; this higher pharmacy cost is not offset by reduced medical cost during the same period. Payers and providers should consider these cost patterns in both coverage and treatment decisions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Evernorth Health Services, Evernorth Research Institute, St. Louis, Missouri, USA.
- FastHSR, Glen Allen, Virginia, USA.
ORCID profiles: Casey P Durand
Cite
APA
Durand, C. P., Eatherly, M., Yao, A., Dollear, T. J., Inneh, A., & Patel, U. (2026). Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study. Diabetes, Obesity and Metabolism, 28(9), 7916-7922. https://doi.org/10.1111/dom.70923
Vancouver
Durand CP, Eatherly M, Yao A, Dollear TJ, Inneh A, Patel U. Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study. Diabetes, Obesity and Metabolism. 2026;28(9):7916-7922. doi:10.1111/dom.70923
BibTeX
@article{Durand2026,
author = {Durand, Casey P and Eatherly, Mark and Yao, Aaron and Dollear, Timothy J and Inneh, Angela and Patel, Urvashi},
title = {Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {7916--7922},
doi = {10.1111/dom.70923}
}
EUVIMED